Cytokinetics Inc. (CYTK)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Cytokinetics Inc. (CYTK)
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Key Insights
Critical company metrics and information
Share Price
$50.48Market Cap
$5.96 BillionTotal Outstanding Shares
118.01 Million SharesTotal Employees
564Dividend
No dividendIPO Date
April 29, 2004SIC Description
Pharmaceutical PreparationsHomepage
https://www.cytokinetics.com
Historical Stock Splits
If you bought 1 share of CYTK before June 25, 2013, you'd have 0.17 shares today.
Execution Date | Split Amount |
---|---|
June 25, 2013 | 1-for-6 (Reverse Split) |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Investing Activities | $-745.37 Million |
Net Cash Flow From Operating Activities, Continuing | $-404.36 Million |
Net Cash Flow From Financing Activities | $1.10 Billion |
Net Cash Flow | $-52.80 Million |
Net Cash Flow From Operating Activities | $-404.36 Million |
Exchange Gains/Losses | $-103,000.00 |
Net Cash Flow, Continuing | $-52.70 Million |
Net Cash Flow From Investing Activities, Continuing | $-745.37 Million |
Net Cash Flow From Financing Activities, Continuing | $1.10 Billion |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Diluted Average Shares | $110,790.00 |
Diluted Earnings Per Share | $-5.38 |
Operating Income/Loss | $-524.63 Million |
Other Operating Expenses | $197.09 Million |
Research and Development | $330.75 Million |
Interest Expense, Operating | $35.93 Million |
Income/Loss From Continuing Operations After Tax | $-576.40 Million |
Basic Average Shares | $110,790.00 |
Nonoperating Income/Loss | $44.11 Million |
Operating Expenses | $527.85 Million |
Net Income/Loss | $-576.40 Million |
Net Income/Loss Attributable To Parent | $-576.40 Million |
Income/Loss From Continuing Operations Before Tax | $-576.40 Million |
Net Income/Loss Available To Common Stockholders, Basic | $-576.40 Million |
Revenues | $3.22 Million |
Costs And Expenses | $579.62 Million |
Benefits Costs and Expenses | $579.62 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Basic Earnings Per Share | $-5.38 |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Wages | $27.88 Million |
Fixed Assets | $64.22 Million |
Accounts Payable | $11.58 Million |
Liabilities | $1.45 Billion |
Equity Attributable To Parent | $-13.91 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Cash | $1.30 Billion |
Noncurrent Liabilities | $1.34 Billion |
Long-term Debt | $619.95 Million |
Current Liabilities | $109.81 Million |
Equity | $-13.91 Million |
Other Non-current Liabilities | $720.21 Million |
Assets | $1.44 Billion |
Other Non-current Assets | $353.24 Million |
Noncurrent Assets | $417.46 Million |
Liabilities And Equity | $1.44 Billion |
Current Assets | $1.02 Billion |
Other Current Liabilities | $70.35 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.